Anti-tumor medicament based on adenovirus

US10851359B2 · kind B2 · utility

Assignee

• MEDIZINISCHE HOCHSCHULE HANNOVER · DE

Inventors

• Rita Gerardy-Schahn · Hiddenhausen, DE
• Florian Kuehnel · Hannover, DE
• Nikolas Martin · Springe, DE
• David Schwarzer · Hannover, DE

Key dates

• Filing date: Mar 24, 2016
• Grant date: Dec 1, 2020
• Expiry date: Aug 28, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2795/00071
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.